Sumitomo Pharma Valuation
Is DNPU.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DNPU.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DNPU.F ($3.8) is trading below our estimate of fair value ($7.31)
Significantly Below Fair Value: DNPU.F is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DNPU.F?
Key metric: As DNPU.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is DNPU.F's PS Ratio? | |
|---|---|
| PS Ratio | 0.7x |
| Sales | JP¥342.67b |
| Market Cap | JP¥231.62b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | -2.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does DNPU.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.7x | ||
NDOI Endo | 1x | n/a | US$1.8b |
LGND Ligand Pharmaceuticals | 15.2x | 15.0% | US$2.3b |
INVA Innoviva | 3.4x | 6.4% | US$1.2b |
SUPN Supernus Pharmaceuticals | 3.1x | 5.9% | US$2.0b |
DNPU.F Sumitomo Pharma | 0.7x | 4.0% | US$231.6b |
Price-To-Sales vs Peers: DNPU.F is good value based on its Price-To-Sales Ratio (0.7x) compared to the peer average (5.7x).
Price to Sales Ratio vs Industry
How does DNPU.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: DNPU.F is good value based on its Price-To-Sales Ratio (0.7x) compared to the US Pharmaceuticals industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is DNPU.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate DNPU.F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | US$3.53 0% | 23.9% | US$4.90 | US$2.42 | n/a | 8 |
| Nov ’25 | n/a | US$3.47 0% | 23.5% | US$4.89 | US$2.41 | n/a | 8 |
| Oct ’25 | n/a | US$3.48 0% | 24.6% | US$5.20 | US$2.57 | n/a | 8 |
| Sep ’25 | n/a | US$3.48 0% | 24.6% | US$5.20 | US$2.57 | n/a | 8 |
| Aug ’25 | n/a | US$2.15 0% | 25.1% | US$2.79 | US$1.23 | n/a | 8 |
| Jul ’25 | n/a | US$2.10 0% | 25.1% | US$2.72 | US$1.20 | n/a | 8 |
| Jun ’25 | n/a | US$2.09 0% | 22.7% | US$2.69 | US$1.22 | n/a | 8 |
| May ’25 | n/a | US$2.16 0% | 18.5% | US$2.72 | US$1.62 | n/a | 8 |
| Apr ’25 | n/a | US$2.70 0% | 47.8% | US$5.80 | US$1.67 | n/a | 8 |
| Mar ’25 | n/a | US$2.75 0% | 46.0% | US$5.79 | US$1.66 | n/a | 8 |
| Feb ’25 | US$2.79 | US$3.26 +17.0% | 36.3% | US$5.95 | US$1.71 | n/a | 8 |
| Jan ’25 | US$3.13 | US$3.42 +9.4% | 34.9% | US$6.15 | US$1.84 | n/a | 8 |
| Dec ’24 | n/a | US$3.24 0% | 33.5% | US$5.74 | US$1.72 | n/a | 8 |
| Nov ’24 | US$2.97 | US$3.39 +14.2% | 28.6% | US$5.81 | US$2.61 | n/a | 8 |
| Oct ’24 | US$3.64 | US$3.45 -5.1% | 30.4% | US$5.88 | US$2.64 | n/a | 7 |
| Sep ’24 | US$3.72 | US$3.65 -1.9% | 29.7% | US$5.95 | US$2.67 | n/a | 8 |
| Aug ’24 | n/a | US$4.80 0% | 23.3% | US$6.70 | US$3.63 | n/a | 8 |
| Jul ’24 | US$4.37 | US$5.52 +26.3% | 23.0% | US$7.17 | US$3.80 | n/a | 7 |
| Jun ’24 | US$5.18 | US$6.09 +17.6% | 21.1% | US$7.87 | US$3.79 | n/a | 7 |
| May ’24 | US$6.21 | US$6.92 +11.4% | 11.4% | US$8.00 | US$5.45 | n/a | 7 |
| Apr ’24 | n/a | US$6.77 0% | 11.6% | US$8.10 | US$5.52 | n/a | 7 |
| Mar ’24 | US$6.38 | US$6.96 +9.2% | 10.7% | US$8.17 | US$5.57 | n/a | 7 |
| Feb ’24 | US$7.00 | US$7.83 +11.9% | 11.0% | US$9.24 | US$6.70 | US$2.79 | 7 |
| Jan ’24 | n/a | US$7.13 0% | 10.5% | US$8.29 | US$6.01 | US$3.13 | 7 |
| Dec ’23 | n/a | US$7.13 0% | 10.5% | US$8.29 | US$6.01 | n/a | 7 |
| Nov ’23 | US$6.89 | US$7.13 +3.5% | 10.5% | US$8.29 | US$6.01 | US$2.97 | 7 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
BeiGene
US$21.9b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
BGNE
US$206.16
7D
8.2%
1Y
10.0%
Collegium Pharmaceutical
US$990.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.71
7D
2.5%
1Y
20.0%
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$201.43
7D
-0.2%
1Y
-7.1%